Active Recombinant Human TNFSF14 protein, hFc-Myc-tagged
Cat.No. : | TNFSF14-4603H |
Product Overview : | Recombinant Human TNFSF14 protein(O43557)(74-240aa), fused to N-terminal hFc tag and Myc tag, was expressed in Mammalian cell. |
- Specification
- Gene Information
- Related Products
- Download
Source : | Mammalian cell |
Species : | Human |
Tag : | Fc&Myc |
Form : | If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. |
Bio-activity : | Measured by its binding ability in a functional ELISA. Immobilized TNFRSF14 at 5 μg/ml can bind TNFSF14, the EC50 is 45.44-53.29 ng/ml. |
Molecular Mass : | 46.7 kDa |
Protein length : | 74-240aa |
AA Sequence : | DGPAGSWEQLIQERRSHEVNPAAHL TGANSSLTGSGGPLLWETQLGLAFL RGLSYHDGALVVTKAGYYYIYSKVQ LGGVGCPLGLASTITHGLYKRTPRY PEELELLVSQQSPCGRATSSSRVWW DSSFLGGVVHLEAGEKVVVRVLDER LVRLRDGTRSYFGAFMV |
Endotoxin : | Less than 1.0 EU/ug as determined by LAL method. |
Purity : | Greater than 88% as determined by SDS-PAGE. |
Storage : | Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
Reconstitution : | Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. |
Gene Name : | TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens ] |
Official Symbol : | TNFSF14 |
Synonyms : | TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML; |
Gene ID : | 8740 |
mRNA Refseq : | NM_003807 |
Protein Refseq : | NP_003798 |
MIM : | 604520 |
UniProt ID : | O43557 |
Products Types
◆ Recombinant Protein | ||
TNFSF14-288H | Recombinant Human TNFSF14 Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
TNFSF14-1544M | Recombinant Mouse TNFSF14 Protein, His-tagged | +Inquiry |
TNFSF14-783C | Recombinant Cynomolgus Monkey TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
TNFSF14-1324H | Acitve Recombinant Human TNFSF14 protein(Asp74-Val240), rFc-tagged | +Inquiry |
TNFSF14-9484M | Recombinant Mouse TNFSF14 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
TNFSF14-891HCL | Recombinant Human TNFSF14 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThe extended longevity of results gave us the confidence to delve deeper into complex biological processes.
It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.
The ability to obtain enduring results positively influenced the depth of our investigations.
Q&As (7)
Ask a questionTNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.
While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.
TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.
TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.
TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.
TNFSF14 has been in pre-clinical development for over a decade.
TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.
Ask a Question for All TNFSF14 Products
Required fields are marked with *
My Review for All TNFSF14 Products
Required fields are marked with *
Inquiry Basket